Unknown

Dataset Information

0

Test-retest reliability of memory task functional magnetic resonance imaging in Alzheimer disease clinical trials.


ABSTRACT: To examine the feasibility and test-retest reliability of encoding-task functional magnetic resonance imaging (fMRI) in mild Alzheimer disease (AD).Randomized, double-blind, placebo-controlled study.Memory clinical trials unit.We studied 12 patients with mild AD (mean [SEM] Mini-Mental State Examination score, 24.0 [0.7]; mean Clinical Dementia Rating score, 1.0) who had been taking donepezil hydrochloride for more than 6 months from the placebo arm of a larger 24-week study (n = 24, 4 scans on weeks 0, 6, 12, and 24, respectively).Placebo and 3 face-name, paired-associate encoding, block-design blood oxygenation level-dependent fMRI scans in 12 weeks.We performed whole-brain t maps (P < .001, 5 contiguous voxels) and hippocampal regions-of-interest analyses of extent (percentage of active voxels) and magnitude (percentage of signal change) for novel-greater-than-repeated face-name contrasts. We also calculated intraclass correlation coefficients and power estimates for hippocampal regions of interest.Task tolerability and data yield were high (95 of 96 scans yielded favorable-quality data). Whole-brain maps were stable. Right and left hippocampal regions-of-interest intraclass correlation coefficients were 0.59 to 0.87 and 0.67 to 0.74, respectively. To detect 25.0% to 50.0% changes in week-0 to week-12 hippocampal activity using left-right extent or right magnitude with 80.0% power (2-sided ? = .05) requires 14 to 51 patients. Using left magnitude requires 125 patients because of relatively small signal to variance ratios.Encoding-task fMRI was successfully implemented in a single-site, 24-week, AD randomized controlled trial. Week 0 to 12 whole-brain t maps were stable, and test-retest reliability of hippocampal fMRI measures ranged from moderate to substantial. Right hippocampal magnitude may be the most promising of these candidate measures in a leveraged context. These initial estimates of test-retest reliability and power justify evaluation of encoding-task fMRI as a potential biomarker for signal of effect in exploratory and proof-of-concept trials in mild AD. Validation of these results with larger sample sizes and assessment in multisite studies is warranted.

SUBMITTER: Atri A 

PROVIDER: S-EPMC3291175 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Test-retest reliability of memory task functional magnetic resonance imaging in Alzheimer disease clinical trials.

Atri Alireza A   O'Brien Jacqueline L JL   Sreenivasan Aishwarya A   Rastegar Sarah S   Salisbury Sibyl S   DeLuca Amy N AN   O'Keefe Kelly M KM   LaViolette Peter S PS   Rentz Dorene M DM   Locascio Joseph J JJ   Sperling Reisa A RA  

Archives of neurology 20110501 5


<h4>Objective</h4>To examine the feasibility and test-retest reliability of encoding-task functional magnetic resonance imaging (fMRI) in mild Alzheimer disease (AD).<h4>Design</h4>Randomized, double-blind, placebo-controlled study.<h4>Setting</h4>Memory clinical trials unit.<h4>Participants</h4>We studied 12 patients with mild AD (mean [SEM] Mini-Mental State Examination score, 24.0 [0.7]; mean Clinical Dementia Rating score, 1.0) who had been taking donepezil hydrochloride for more than 6 mont  ...[more]

Similar Datasets

| S-EPMC7186292 | biostudies-literature
| S-EPMC8090786 | biostudies-literature
| S-EPMC5568997 | biostudies-literature
| S-EPMC10983911 | biostudies-literature
| S-EPMC10619370 | biostudies-literature
| S-EPMC7267954 | biostudies-literature
| S-EPMC4623457 | biostudies-literature
| S-EPMC9980889 | biostudies-literature
| S-EPMC6950610 | biostudies-literature
| S-EPMC7061333 | biostudies-literature